Indication Global
Market Size
Pre
Clinical
Phase
Ib
Phase
IIb
EU Conditional
Marketing Approval
Post EU
Marketing
US Phase 3
Treatment of organ failure associated with Sepsis $33B   Completed Phase IIb Initiation Q4-4 2020    
               
Treatment of organ failure associated with COVID-19 $1B   Completed Phase II Ongoing    
               
Prevention of post-Bone Marrow Transplantations (BMT) complications $3B     Phase IIa Completed, Phase II Initiation 2022    
               
Solid tumor “immune checkpoint” microenvironment modulation $4B Completed